Hybrid Closed-Loop Systems to Date: Hype Versus Reality

Forlenza GP , Pinhas-Hamiel O , Liljenquist DR , et al. Safety evaluation of the MiniMed 670G system in children 7–13 years of age with type 1 diabetes. Diabetes Technol Ther, 2019; 21(1):11–doi: 10.1089/dia.2018.0264

Garg SK , Weinzimer SA , Tamborlane WV , et al. Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther, 2017; 19(3):155–doi: 10.1089/dia.2016.0421

Forlenza GP , Buckingham BA , Brown SA , et al. First outpatient evaluation of a tubeless automated insulin delivery system with customizable glucose targets in children and adults with type 1 diabetes. Diabetes Technol Ther, 2021; 23(6):410–doi: 10.1089/dia.2020.0546

Buckingham BA , Christiansen MP , Forlenza GP , et al. Performance of the omnipod personalized model predictive control algorithm with meal bolus challenges in adults with type 1 diabetes. Diabetes Technol Ther, 2018; 20(9):585–doi: 10.1089/dia.2018.0138

Buckingham BA , Forlenza GP , Pinsker JE , et al. Safety and feasibility of the OmniPod hybrid closed-loop system in adult, adolescent, and pediatric patients with type 1 diabetes using a personalized model predictive control algorithm. Diabetes Technol Ther, 2018; 20(4):257–doi: 10.1089/dia.2017.0346

Breton MD , Kanapka LG , Beck RW , et al. A randomized trial of closed-loop control in children with type 1 diabetes. N Engl J Med, 2020; 383(9):836–doi: 10.1056/NEJMoa2004736

Brown SA , Beck RW , Raghinaru D , et al. Glycemic outcomes of use of CLC versus PLGS in type 1 diabetes: A randomized controlled trial. Diabetes Care, 2020; 43(8):1822–doi: 10.2337/dc20-0124

Forlenza GP , Ekhlaspour L , Breton M , et al. Successful at-home use of the tandem control-IQ artificial pancreas system in young children during a randomized controlled trial. Diabetes Technol Ther, 2019; 21(4):159–doi: 10.1089/dia.2019.0011

Ware J , Allen JM , Boughton CK , et al. Randomized trial of closed-loop control in very young children with type 1 diabetes. N Engl J Med, 2022; 386(3):209–doi: 10.1056/NEJMoa2111673

Carlson AL , Sherr JL , Shulman DI , et al. Safety and glycemic outcomes during the MiniMed™ advanced hybrid closed-loop system pivotal trial in adolescents and adults with type 1 diabetes. Diabetes Technol Ther, 2022; 24(3):178–doi: 10.1089/dia.2021.0319

Messer LH. Why expectations will determine the future of artificial pancreas. Diabetes Technol Ther, 2018; 20(S2):S265–S268; doi: 10.1089/dia.2018.0116

Gartner Inc . Hype Cycle Research Methodology. Available from: www.gartner.com/technology/research/methodologies/hype-cycle.jsp [Last accessed: June 15, 2022].

Fenn J , Raskino M. Mastering the Hype Cycle: How to Choose the Right Innovation at the Right Time. Boston, MA: Harvard Business Press; 2008; p. 256.

Rogers E. Diffusion of Innovation. New York, NY: Free Press; 2003.

Castañeda J , Mathieu C , Aanstoot HJ , et al. Predictors of time in target glucose range in real-world users of the MiniMed 780G system. Diabetes Obes Metab 2022; doi: 10.1111/dom.14807

Forlenza GP , Vigers T , Berget C , et al. Predicting success with a first-generation hybrid closed-loop artificial pancreas system among children, adolescents, and young adults with type 1 diabetes: A model development and validation study. Diabetes Technol Ther, 2022; 24(3):157–doi: 10.1089/dia.2021.0326

Arrieta A , Battelino T , Scaramuzza AE , et al. Comparison of MiniMed 780G system performance in users aged younger and older than 15 years: Evidence from 12 870 real-world users. Diabetes Obes Metab, 2022; 24(7):1370–doi: 10.1111/dom.14714

Silva JD , Lepore G , Battelino T , et al. Real-world performance of the MiniMed™ 780G system: First report of outcomes from 4120 users. Diabetes Technol Ther, 2022; 24(2):113–doi: 10.1089/dia.2021.0203

Battelino T , Danne T , Bergenstal RM , et al. Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the International Consensus on Time in Range. Diabetes Care, 2019; 42(8):1593–doi: 10.2337/dci19-0028

Vigersky RA , McMahon C . The relationship of hemoglobin A1C to time-in-range in patients with diabetes. Diabetes Technol Ther, 2019; 21(2):81–doi: 10.1089/dia.2018.0310

Beck RW , Bergenstal RM , Cheng P , et al. The relationships between time in range, hyperglycemia metrics, and HbA1c. J Diabetes Sci Technol, 2019; 13(4):614–doi: 10.1177/1932296818822496

Breton MD , Kovatchev BP . One year real-world use of the control-IQ advanced hybrid closed-loop technology. Diabetes Technol Ther, 2021; 23(9):601–doi: 10.1089/dia.2021.0097

Messer LH , Berget C , Pyle L , et al. Real-world use of a new hybrid closed loop improves glycemic control in youth with type 1 diabetes. Diabetes Technol Ther, 2021; 23(12):837–doi: 10.1089/dia.2021.0165

Arunachalum S , Velado K , Vigersky RA , Cordero TL . Glycemic outcomes during real-world hybrid closed-loop system use by individuals with type 1 diabetes in the United States. J Diabetes Sci Technol 2022:19322968221088608; doi: 10.1177/19322968221088608

Berget C , Akturk HK , Messer LH , et al. Real-world performance of hybrid closed loop in youth, young adults, adults and older adults with type 1 diabetes: Identifying a clinical target for hybrid closed-loop use. Diabetes Obes Metab, 2021; 23(9):2048–doi: 10.1111/dom.14441

Weissberg-Benchell J , Shapiro JB , Hood K , et al. Assessing patient-reported outcomes for automated insulin delivery systems: The psychometric properties of the INSPIRE measures. Diabet Med, 2019; 36(5):644–doi: 10.1111/dme.13930

Venkatesh V , Davis FD . A theoretical extension of the technology acceptance model: Four longitudinal field studies. Manag Sci, 2000; 46(2):186–204.

Davis FD. Perceived usefulness, perceived ease of use, and user acceptance of information technology. Manag Inform Syst Q, 1989; 13(3):319–340.

O'Malley G , Messer LH , Levy CJ , et al. Clinical management and pump parameter adjustment of the control-IQ closed-loop control system: Results from a 6-month, multicenter, randomized clinical trial. Diabetes Technol Ther, 2021; 23(4):245–doi: 10.1089/dia.2020.0472

Messer LH , Forlenza GP , Sherr JL , et al. Optimizing hybrid closed-loop therapy in adolescents and emerging adults using the MiniMed 670G system. Diabetes Care, 2018; 41(4):789–doi: 10.2337/dc17-1682

Berget C , Sherr JL , DeSalvo DJ , et al. Clinical implementation of the Omnipod 5 automated insulin delivery system: Key considerations for training and onboarding people with diabetes. Clin Diabetes, 2022; 40(2):168–doi: 10.2337/cd21-0083

Messer LH , Berget C , Forlenza GP . A clinical guide to advanced diabetes devices and closed-loop systems using the CARES paradigm. Diabetes Technol Ther, 2019; 21(8):462–doi: 10.1089/dia.2019.0105

Greenwood DA , Howell F , Scher L , et al. A framework for optimizing technology-enabled diabetes and cardiometabolic care and education: The role of the diabetes care and education specialist. Diabetes Educ, 2020; 46(4):315–doi: 10.1177/0145721720935125

Ridley M. Amara's Law. Available from: https://www.rationaloptimist.com/blog/amaras-law/ [Last accessed: August 1, 2022].